National Taiwan University Hospital - Recruiting 7 years to 16 years. - A Study to Identify the Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in Attention Deficit Hyperactivity Disorder.
Shire Development LLC - Recruiting 13 years to 17 years. - A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSEr) Compared With OROS-MPH (CONCERTAr) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD).
Arbor Pharmaceuticals, Inc. - Recruiting 6 years to 12 years. - A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom.
University of California, Los Angeles - Recruiting 9 years to 14 years. - An Eight-Week, Open Trial Pilot Investigation of Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD).
National Taiwan University Hospital - Recruiting 18 years to 50 years. - The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults With Attention Deficit/Hyperactivity Disorder.
Johannes Gutenberg University Mainz - Recruiting 6 years to 17 years. - Efficacy and Safety of St. John's Wort/Valerian Extract (Sedariston Concentrate) Versus Placebo in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD).